Tear Film Insufficiency — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for tear film insufficiency. 25 active patents protecting 2 drugs from 2+ originators. First major cliff: 2029. Daily refresh.

2
Approved drugs
25
Active US patents
54/100
Avg vulnerability
$1.9B
Annual revenue covered

Originators in Tear Film Insufficiency

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Novartis AG (originally Sandoz) 17 patents Bausch Health 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating tear film insufficiency. Each bar = one year. Y-axis scaled to peak year (5 patents).

1
27
4
29
4
30
1
31
1
32
5
33
2
34
1
36
3
37
1
38
1
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Sandimmune
cyclosporine
 Novartis AG (originally Sandoz) 17 55 $1.9B 2027-11-03
Xiidra
LIFITEGRAST
 Bausch Health 8 52 — 2029-04-15

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9447077 Xiidra method of use 75 2029-04-15
8367701 Xiidra method of use 75 2029-04-15
8168655 Xiidra method of use 75 2029-05-09
12496326 Sandimmune method of use 75 2036-09-29
11951153 Sandimmune method of use 75 2037-02-28
12059449 Sandimmune method of use 75 2042-04-01
11154513 Sandimmune method of use 70 2038-11-20
11413323 Sandimmune method of use 70 2039-10-11
9937225 Sandimmune method of use 62 2033-08-23
8980839 Sandimmune method of use 62 2033-08-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9890141 Xiidra composition of matter 10 2030-10-21
10918694 Sandimmune formulation 42 2037-02-28
9669974 Sandimmune formulation 42 2034-05-11
9676525 Sandimmune formulation 42 2034-02-07
11058677 Xiidra formulation 42 2033-12-18
10441630 Sandimmune formulation 42 2033-08-23
9085553 Xiidra formulation 42 2033-07-25
8561859 Sandimmune formulation 48 2032-04-16
8292129 Sandimmune formulation 48 2031-02-25
8927574 Xiidra formulation 48 2030-11-12

Related